THERE IS SOME POSITIVE LAB INDUSTRY NEWS that has not been widely reported yet. It involves a decision to change an unwelcome Medicare policy that limited the number of prostate biopsy specimens per case that would be reimbursed. After discussions between lab industry groups and the federal Centers for Medicare & Medicaid Services (CMS), Palmetto […]
- "Payer Update"
Palmetto’s Prostate Biopsy Policy Removed after Talks with CMS
Action is a welcome development for labs, but uncertainty remains about unpaid claims
- By Robert Michel
- > From the Volume XX No. 3 - March 4, 2013 Issue
